NCT06375460

Brief Summary

This is a clinical trial that includes a run-in period, a 90 day micro-randomized trial, and a 90-day observational period. The goal of this study is to evaluate whether providing paired real time glycemic and health behavior data in a smartphone app leads to better glycemic control among adolescents and young adults with T2D. Glycemic control will be monitored using Continuous Glucose Monitors (CGM), and health behavior data will be collected via a Fitbit activity tracker and a research app (Healthmine). Participants will be prompted to view and reflect on glycemic trends and health behavior data (Fitbit data, logging of diet and medication adherence) during the 90-day micro-randomized trial period, then observed for ongoing use of the Healthmine app and engagement with CGM in the following 90-day observation period.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus-type-2

Timeline
38mo left

Started Jul 2026

Longer than P75 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 14, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 19, 2024

Completed
2.2 years until next milestone

Study Start

First participant enrolled

July 1, 2026

Expected
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2029

1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2029

Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

3 years

First QC Date

March 14, 2024

Last Update Submit

April 22, 2026

Conditions

Outcome Measures

Primary Outcomes (16)

  • Glucose time above 180mg/dL

    measured using continuous glucose monitor

    daily during micro randomized trial, 90 days

  • Mean daily glucose

    measured using continuous glucose monitor; mg/dL

    daily during micro randomized trial, 90 days

  • Maximum daily glucose

    measured using continuous glucose monitor; mg/dL

    daily during micro randomized trial, 90 days

  • Minimum daily glucose

    measured using continuous glucose monitor; mg/dL

    daily during micro randomized trial, 90 days

  • Glucose coefficient of variability

    measured using continuous glucose monitor

    daily during micro randomized trial, 90 days

  • Mean amplitude of glycemic excursions

    measured using continuous glucose monitor

    daily during micro randomized trial, 90 days

  • Hemoglobin A1c

    lab-based measure to assess longer-term glycemic control, collected at study visit

    through study completion, 6 months average

  • Fasting glucose

    lab-based measure to assess glycemic control, collected at study visit

    through study completion, 6 months average

  • Objective physical activity (step count)

    step count measured using the Fitbit physical activity tracker

    daily during micro randomized trial, 90 days;

  • Objective physical activity (moderate-vigorous physical activity)

    moderate-vigorous physical activity (\>100 steps per minute) will be measured using Fitbit activity tracker

    daily during micro randomized trial, 90 days;

  • Self-reported physical activity

    assessed using PACE+ Adolescent Physical Activity Measure (PACE+) questionnaire to determine days with at least 60 minutes of moderate-vigorous physical activity per week. score ranges from 0-14; lower scores indicate less achievement of physical activity guidelines

    through study completion, 6 months average

  • Diet quality

    24-hour dietary recall will be collected by study staff, who will use the Automated Self Administered 24 Hour Dietary Recall Assessment Tool (ASA24) to record data for diet quality assessment

    through study completion, 6 months average

  • Capability

    Assessed via the Diabetes Empowerment Scale (DES), a measure of self-efficacy. Average score ranges from 28-140; higher scores indicate greater diabetes empowerment

    through study completion, 6 months average

  • Healthmine app use

    Percent of days with app use, per study period will be determined.

    during microrandomized trial, observational period

  • Continuous glucose monitor use use

    Defined as percent of days with CGM data available, per study period.

    during microrandomized trial, observational period

  • Motivation to engage in diabetes self-management

    Measured via Treatment Self-Regulation Questionnaire (TSRQ). score ranges from 15-105; scoring is based on and average between subscales of intrinsic vs. extrinsic motivation.

    through study completion, 6 months average

Secondary Outcomes (2)

  • Body Mass Index (BMI)

    through study completion, 6 months average

  • Diabetes distress

    through study completion; 6 months average

Study Arms (4)

Physical Activity Focused App Prompt

EXPERIMENTAL

The app prompts will ask participants what went well, or did not go well with their physical activity in the previous 24 hours in relation to their blood glucose numbers.

Behavioral: Focused App Prompt

Diet Focused App Prompt

EXPERIMENTAL

The app prompts will ask participants what went well, or did not go well with their diet in the previous 24 hours in relation to their blood glucose numbers.

Behavioral: Focused App Prompt

No App Prompt

EXPERIMENTAL

No app prompt will be sent to the participant

Behavioral: No App Prompt

Outreach for Missing Data

EXPERIMENTAL

Participants will be randomized to receive proactive outreach by the study team in the case of 3 or more days of missing CGM data, versus no proactive outreach

Behavioral: Outreach for Missing Data

Interventions

Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).

Diet Focused App PromptPhysical Activity Focused App Prompt
No App PromptBEHAVIORAL

No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.

No App Prompt

For participants randomized to proactive outreach, after 3 or more days of missing CGM data, the study team will reach out to participants by phone and/or text message to troubleshoot and support participants in re-connecting with CGM and apps. For participants randomized to not receive proactive outreach, participants will be instructed to reach out to the study team at their discretion when help is needed related to CGM or app connection.

Outreach for Missing Data

Eligibility Criteria

Age16 Years - 24 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • type 2 diabetes: negative diabetes autoantibodies, no suspicion for monogenic diabetes
  • HbA1c ≥7.0%, stable medication use
  • HbA1c 6.0-6.9% without short-acting insulin, any other stable diabetes medication use
  • English-speaking (app in English)

You may not qualify if:

  • Current pregnancy
  • Hydroxyurea use (CGM sensor inaccuracies)
  • Cognitive impairment or severe psychiatric condition that could interfere with participation in behavioral intervention for diabetes self-management
  • Current or previously diagnosed eating disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2HyperglycemiaSedentary Behavior

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesBehavior

Study Officials

  • Mary Ellen Vajravelu, MD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mary Ellen Vajravelu, MD

CONTACT

Margaret Zupa, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Subjects will wear a continuous glucose monitor and activity watch for study duration. Subjects will be micro-randomized once daily for 90 days to receive app prompts regarding nutrition or physical activity.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 14, 2024

First Posted

April 19, 2024

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

August 1, 2029

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, appendices)

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Beginning 3 months and ending 5 years following article publication
Access Criteria
proposals should be directed to vajravelume@upmc.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years

Locations